EU agency backs new drugs from GSK, Gilead, Otsuka
LONDON Nov 22 (Reuters) - European regulators said on Friday they had recommended approval of a new drug for HIV from GlaxoSmithKline and a novel hepatitis C treatment from Gilead Sciences.
The European Medicine Agency (EMA) also gave a green light to an Otsuka tuberculosis drug, following a review of an earlier rejection.
Recommendations for marketing approval by the EMA's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.
- Malaysia air force chief denies saying lost plane tracked to west |
- Malaysia military source says missing jet veered to west |
- Toddler found with heroin at New Jersey daycare center
- Ukraine appeals to the West as Crimea turns to Russia |
- UPDATE 1-Missing Malaysian plane last seen at Strait of Malacca-source